medigraphic.com
Instituto Nacional de Salud Pública

2022, Number 2

<< Back Next >>

salud publica mex 2022; 64 (2)

Effectiveness of SARS-CoV-2 vaccines in hospitalized patients with vaccine failures in 10 CCINSHAE hospitals

Pérez-Padilla JR, Mora-Pavón A, Hernández-Cárdenas CM, Galindo-Fraga A, Kawa-Karasik S, Espinoza-Bautista KA, Reyes-Terán G

Language: Spanish
References: 13
Page: 131-136
PDF size: 208.71 Kb.


ABSTRACT

Objective. To evaluate the effectiveness of SARS-CoV-2 vaccines to avoid death and intubation in hospitalized patients with Covid-19. Materials and methods. We present an analysis of 3 565 hospitalizations for SARSCoV- 2 in people over 20 years of age, reported for public health purposes by 10 specialty hospitals, comparing those discharged for improvement (2 094) with those who died (1 471) in mixed models of logistic regression adjusted for age, sex, number of comorbidities and the reporting hospital as a random variable. Results. A complete vaccination schedule, with five types of vaccine available, had a protective effect for death or intubation (OR: 0.67, CI95%: 0.54,0.83, 33% protection) and for death (OR: 0.80, CI95%: 0.64,0.99, 20% protection) compared to those who had not been vaccinated. All the applied vaccines in the Mexican program showed a protective effect with an OR<0.8, with variable confidence intervals. Conclusions. Even in patients previously vaccinated and hospitalized with severe Covid-19, a history of vaccination reduces the risks of being intubated and dying.


REFERENCES

  1. Secretaría de Salud. COVID-19 Información Relevante. Comunicado técnico diario. Ciudad de México: SS, 2022 [citado nov 2021]. Disponible en: https://www.gob.mx/salud/documentos/coronavirus-covid-19-comunicado- tecnico-diario-238449

  2. Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review. Clin Microbiol Infect. 2021;21:604-2. https://doi.org/10.1016/j.cmi.2021.10.005

  3. Liu Q, Qin C, Liu M, Liu J. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a sys-tematic review and meta-analysis. Infect Dis Poverty. 2021;10:132.

  4. Tenforde MW, Self WH, Adams K, Gaglani M, Ginde AA, McNeal T, et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. Jama. 2021;326(20):2043-54. https://doi.org/10.1001/ jama.2021.19499

  5. Thompson MG, Stenehjem E, Grannis S, Ball SW, Naleway AL, Ong TC, et al. Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings. N Engl J Med. 2021;385(15):1355-71. https://doi.org/10.1056/ NEJMoa2110362

  6. Singh C, Naik BN, Pandey S, Biswas B, Pati BK, Verma M, et al. Effectiveness of COVID-19 vaccine in preventing infection and disease severity: a case-control study from an Eastern State of India. Epidemiol Infect. 2021;149:e224. https://doi.org/10.1017/S0950268821002247

  7. Self WH, Tenforde MW, Rhoads JP, Gaglani M, Ginde AA, Douin DJ, et al. Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions - United States, March-August 2021. Morb Mortal Wkly Rep. 2021;70:1337-43. https://doi. org/10.15585/mmwr.mm7038e1

  8. Tenforde MW, Patel MM, Ginde AA, Douin DJ, Talbot HK, Casey JD, et al. Effectiveness of SARS-CoV-2 mRNA vaccines for preventing Covid-19 hospitalizations in the United States. MedRxiv [preprint]. 2021. https://doi. org/10.1101/2021.07.08.21259776

  9. Tenforde MW, Self WH, Naioti EA, Ginde AA, Douin DJ, Olson AM, et al. Sustained effectiveness of Pfizer-BioNTech and Moderna Vaccines against COVID-19 associated hospitalizations among adults - United States, March-July 2021. Morb Mortal Wkly Rep. 2021;70:1156-62. https://doi. org/10.15585/mmwr.mm7034e2

  10. Chua H, Feng S, Lewnard JA, Sullivan SG, Blyth CC, Lipsitch M, et al. The use of test-negative controls to monitor vaccine effectiveness: a systematic review of methodology. Epidemiology. 2020;31(1):43-64. https:// doi.org/10.1097/EDE.0000000000001116

  11. Lewnard JA, Patel MM, Jewell NP, Verani JR, Kobayashi M, Tenforde MW, et al. Theoretical framework for retrospective studies of the effectiveness of SARS-CoV-2 vaccines. epidemiology. 2021;32(4):508-17. https://doi. org/10.1097/EDE.0000000000001366

  12. Sullivan SG, Feng S, Cowling BJ. Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review. Expert Rev Vaccines. 2014;13(12):1571-91. https://doi.org/10.1586/14760584.20 14.966695

  13. Consorcio Mexicano de Vigilancia Genómica. MexCov2. México: AHF, Conacyt, 2021 [citado nov 2021]. Disponible en: http://mexcov2.ibt.unam. mx:8080/COVID-TRACKER/




2020     |     www.medigraphic.com